Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

AVEO PHARMACEUTICALS INC

Form 4

January 30, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16.

Form 4 or Form 5 obligations

may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

2. Issuer Name and Ticker or Trading

AVEO PHARMACEUTICALS INC

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

HA NGOC TUAN

[AVEO]

Symbol

(Last) (First)

CAMBRIDGE, MA 02142

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year) 01/29/2014

INC., 650 E. KENDALL STREET

(Street)

C/O AVEO PHARMACEUTICALS.

4. If Amendment, Date Original

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

(Check all applicable)

Chief Executive Officer

10% Owner

Other (specify

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Issuer

below)

_X__ Director

Applicable Line)

X_ Officer (give title

(City)

1. Title of

Security

(Instr. 3)

2. Transaction Date 2A. Deemed

(State)

(Zip)

(Month/Day/Year) Execution Date, if

3. Code (Month/Day/Year) (Instr. 8)

TransactionAcquired (A) or

Code V Amount (D) Price

4. Securities

Disposed of (D) (Instr. 3, 4 and 5)

(A)

or

Securities Owned Following

Beneficially Reported Transaction(s)

(Instr. 3 and 4)

5. Amount of

(I) (Instr. 4)

6. Ownership

Form: Direct

(Instr. 4)

Ownership

Indirect

(D) or Indirect Beneficial

7. Nature of

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Conversion

3. Transaction Date 3A. Deemed

(Month/Day/Year) Execution Date, if

5. Number of TransactionDerivative

6. Date Exercisable and **Expiration Date**

7. Title and Amou Underlying Securi

Edgar Filing: AVEO PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)		Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo Num Shar
Stock Option (right-to-buy)	\$ 1.77	01/29/2014		A		100,000		<u>(1)</u>	01/29/2024	Common Stock	100

Relationships

Reporting Owners

Reporting Owner Name / Address			F	
	Director	10% Owner	Officer	Other
HA NGOC TUAN C/O AVEO PHARMACEUTICALS, INC. 650 E. KENDALL STREET CAMBRIDGE, MA 02142	X		Chief Executive Officer	

Signatures

/s/Joseph D. Vittiglio, Esq.,
attorney-in-fact 01/30/2014

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests in equal monthly installments from January 1, 2014 through January 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2